Assembly Biosciences Doses First Participant In Phase 1a Clinical Study Of Oral Entry Inhibitor Candidate ABI-6250 For Hepatitis Delta Virus; Phase 1a Study Will Evaluate Single And Multiple Ascending Doses Of ABI-6250 In Healthy Participants With...

BenzingaFeb 26 08:04 ET

Express News | Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate Abi-6250 for Hepatitis Delta Virus

ReutersFeb 26 08:00 ET

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly BiosciencesFeb 26 00:00 ET

Assembly Biosciences Advances ABI-1179 to Phase 1b in Clinical Study for Recurrent Genital Herpes With Promising Interim Results

Quiver QuantitativeFeb 20 08:13 ET

Express News | Assembly Biosciences: Phase 1B to Run Concurrently With Ongoing Phase 1B Study for Abi-5366, Interim Data for Both Candidates Expected in Fall 2025

ReutersFeb 20 08:05 ET

Express News | Assembly Biosciences Inc: Abi-1179 Was Well-Tolerated

ReutersFeb 20 08:00 ET